Is the Capsaicin 179 mg (8% w/w) Cutaneous Patch an Appropriate Treatment Option for Older Patients with Peripheral Neuropathic Pain?

References

• Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–1635. doi:10.1212/01.wnl.0000282763.29778.59
   PubMed Web of Science ®Google Scholar
• Stompór M, Grodzicki T, Stompór T, Wordliczek J, Dubiel M, Kurowska I. Prevalence of chronic pain, particularly with neuropathic component, and its effect on overall functioning of elderly patients. Med Sci Monit. 2019;25:2695–2701. doi:10.12659/MSM.911260
   PubMed Web of Science ®Google Scholar
• Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012;16(3):191–198. doi:10.1007/s11916-012-0256-0
   PubMed Web of Science ®Google Scholar
• Allegri M, Baron R, Hans G, et al. A pharmacological treatment algorithm for localized neuropathic pain. Curr Med Res Opin. 2016;32(2):377–384. doi:10.1185/03007995.2015.1129321
   PubMed Web of Science ®Google Scholar
• Saraiva MD, Suzuki GS, Lin SM, de Andrade DC, Jacob-Filho W, Suemoto CK. Persistent pain is a risk factor for frailty: a systematic review and meta-analysis from prospective longitudinal studies. Age Ageing. 2018;47(6):785–793. doi:10.1093/ageing/afy104
   PubMed Web of Science ®Google Scholar
• Pickering G, Martin E, Tiberghien F, Delorme C, Mick G. Localized neuropathic pain: an expert consensus on local treatments. Drug Des Devel Ther. 2017;11:2709–2718. doi:10.2147/DDDT.S142630
   PubMed Web of Science ®Google Scholar
• Pickering G, Lucchini C. Topical treatment of localized neuropathic pain in the elderly. Drugs Aging. 2020;37(2):83–89. doi:10.1007/s40266-019-00739-9
   PubMed Web of Science ®Google Scholar
• Luchting B, Azad SC. Pain therapy for the elderly patient: is opioid-free an option? Curr Opin Anaesthesiol. 2019;32(1):86–91. doi:10.1097/ACO.0000000000000675
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. doi:10.1016/S1474-4422(14)70251-0
   PubMed Web of Science ®Google Scholar
• Moisset X, Bouhassira D, Avez Couturier J, et al. Pharmacological andnon-pharmacological treatments for neuropathic pain: systematic review and Frenchrecommendations. Rev Neurol. 2020;176(5):325–352. doi:10.1016/j.neurol.2020.01.361
   PubMedGoogle Scholar
• Averitas Pharma Inc. Prescribing information. QUTENZA® (capsaicin) topical system. 2022. www.fda.gov/medwatch. Accessed November 10, 2022.
   Google Scholar
• Grunenthal Ltd. Qutenza 179 mg cutaneous patch;2022. Available from: https://www.medicines.org.uk/emc/product/573/smpc. Accessed November 10, 2022.
   Google Scholar
• Haanpää M, Cruccu G, Nurmikko TJ, et al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur J Pain. 2016;20(2):316–328. doi:10.1002/ejp.731
   PubMed Web of Science ®Google Scholar
• van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 2017;39(4):787–803.e18. doi:10.1016/j.clinthera.2017.02.010
   PubMed Web of Science ®Google Scholar
• Kopsky DJ, van Eijk RPA, Warendorf JK, Keppel Hesselink JM, Notermans NC, Afje V. Enriched enrollment randomized double-blind placebo-controlled cross-over trial with phenytoin cream in painful chronic idiopathic axonal polyneuropathy (EPHENE): a study protocol. Trials. 2022;23(1):888. doi:10.1186/s13063-022-06806-8
   PubMedGoogle Scholar
• Lippi L, de Sire A, Folli A, et al. Multidimensional effectiveness of botulinum toxin in neuropathic pain: a systematic review of randomized clinical trials. Toxins. 2022;14(5):308. doi:10.3390/toxins14050308
   PubMed Web of Science ®Google Scholar
• Quintero JM, Pulido G, Giraldo LF, Leon MX, Diaz LE, Bustos RH. A systematic review on cannabinoids for neuropathic pain administered by routes other than oral or inhalation. Plants. 2022;11(10):1357. doi:10.3390/plants11101357
   Google Scholar
• Backonja M, Malan TP, Vanhove GF, Tobias JK. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11(4):600–608. doi:10.1111/j.1526-4637.2009.00793.x
   PubMed Web of Science ®Google Scholar
• Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain. 2010;11(10):972–982. doi:10.1016/j.jpain.2010.01.270
   PubMed Web of Science ®Google Scholar
• Webster LR, Tark M, Rauck R, Tobias JK, Vanhove GF. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurol. 2010;10(1):92.
   PubMedGoogle Scholar
• Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12:99–109. doi:10.1111/j.1526-4637.2010.01004.x
   PubMed Web of Science ®Google Scholar
• Webster LR, Nunez M, Tark MD, et al. Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia. BMC Anesthesiol. 2011;11:25. doi:10.1186/1471-2253-11-25
   PubMed Web of Science ®Google Scholar
• Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42–53. doi:10.1016/j.jpain.2016.09.008
   PubMed Web of Science ®Google Scholar
• Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16(1):251. doi:10.1186/s12883-016-0752-7
   PubMed Web of Science ®Google Scholar
• Simpson DM, Brown S, Tobias JK, Vanhove GF. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy results of a 52-week open-label study. Clin J Pain. 2014;30(2):134–142. doi:10.1097/AJP.0b013e318287a32f
   PubMed Web of Science ®Google Scholar
• Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305–2313. doi:10.1212/01.wnl.0000314647.35825.9c
   PubMed Web of Science ®Google Scholar
• Simpson DM, Estanislao L, Brown SJ, Sampson J. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. J Pain Symptom Manage. 2008;35(3):299–306. doi:10.1016/j.jpainsymman.2007.04.015
   PubMed Web of Science ®Google Scholar
• Clifford DB, Simpson DM, Brown S, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr. 2012;59(2):126–133. doi:10.1097/QAI.0b013e31823e31f7
   PubMed Web of Science ®Google Scholar
• Webster LR, Peppin JF, Murphy FT, Tobias JK, Vanhove GF. Tolerability of NGX-4010, a capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain. J Pain Res. 2012;5:7–13.
   PubMedGoogle Scholar
• Simpson DM, Gazda S, Brown S, et al. Long-term safety of ngx-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage. 2010;39(6):1053–1064.
   PubMed Web of Science ®Google Scholar
• Gálvez R, Navez ML, Moyle G, et al. Capsaicin 8% patch repeat treatment in nondiabetic peripheral neuropathic pain. Clin J Pain. 2017;33(10):921–931.
   PubMed Web of Science ®Google Scholar
• Jensen TS, Høye K, Fricová J, et al. Tolerability of the capsaicin 8% patch following pretreatment with lidocaine or tramadol in patients with peripheral neuropathic pain: a multicentre, randomized, assessor-blinded study. Eur J Pain. 2014;18(9):1240–1247.
   PubMed Web of Science ®Google Scholar
• Backonja M, Wallace MS, Blonsky R, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7(12):1106–1112. doi:10.1016/S1474-4422(08)70228-X
   PubMed Web of Science ®Google Scholar
• Smith SM, Dworkin RH, Turk DC, et al. Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. Pain. 2020;161(11):2446–2461. doi:10.1097/j.pain.0000000000001952
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. ICH Topic E 7. Studies in support of special populations: geriatrics; 1994. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-7-studies-support-special-populations-geriatrics-step-5_en.pdf. Accessed January 15, 2024.
   Google Scholar
• Little W, Vyain S, Cody-Rydzewski S, et al. Introduction to Sociology; 2014. Available from: https://opentextbc.ca/introductiontosociology/. Accessed March 09, 2024.
   Google Scholar
• Vinik AI. Repeat treatment with capsaicin 8% patch (179mg capsaicin cutaneous patch): effects on pain, quality of life, and patient satisfaction in painful diabetic peripheral neuropathy: an open-label, randomized controlled clinical trial. J Curr Med Res Opinion. 2019;02(12):388–401. doi:10.15520/jcmro.v2i12.242
   Google Scholar
• Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490–502. doi:10.1093/bja/aer260
   PubMed Web of Science ®Google Scholar
• Olsen MF, Bjerre E, Hansen MD, Tendal B, Hilden J, Hróbjartsson A. Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies. J Clin Epidemiol. 2018;101:87–106.e2. doi:10.1016/j.jclinepi.2018.05.007
   PubMed Web of Science ®Google Scholar
• Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol. 2005;11(4):221–235. doi:10.1111/j.0909-725X.2005.00151.x
   PubMed Web of Science ®Google Scholar
• Lachin JM. Fallacies of last observation carried forward analyses. Clin Trials. 2016;13(2):161–168. doi:10.1177/1740774515602688
   PubMed Web of Science ®Google Scholar
• Pickering G, Marcoux M, Chapiro S, et al. An algorithm for neuropathic pain management in older people. Drugs Aging. 2016;33(8):575–583. doi:10.1007/s40266-016-0389-7
   PubMed Web of Science ®Google Scholar
• Holt S, Schmiedl S, Thürmann PA. Potenziell inadäquate medikation für ältere menschen: die PRISCUS-liste. Dtsch Arztebl. 2010;107(31–32):1.
   Google Scholar
• Mukai R, Hasegawa S, Umetsu R, et al. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases. J Clin Pharm Ther. 2019;44(2):285–291. doi:10.1111/jcpt.12790
   PubMed Web of Science ®Google Scholar
• World Health Organization. Falls; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/falls. Accessed November 14, 2022.
   Google Scholar
• Farrell B, French Merkley V, Ingar N. Reducing pill burden and helping with medication awareness to improve adherence. Can Pharm J. 2013;146(5):262–269. doi:10.1177/1715163513500208
   Google Scholar
• Babbar S, Marier JF, Mouksassi MS, et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit. 2009;31(4):502–510. doi:10.1097/FTD.0b013e3181a8b200
   PubMed Web of Science ®Google Scholar
• Aitken E, McColl G, Kingsmore D. The role of Qutenza® (topical capsaicin 8%) in treating neuropathic pain from critical ischemia in patients with end-stage renal disease: an observational cohort study. Pain Med. 2017;18(2):330–340. doi:10.1093/pm/pnw139
   PubMed Web of Science ®Google Scholar
• Schubert T, Kern KU, Schneider S, Baron R. Oral or topical pain therapy—how would patients decide? a discrete choice experiment in patients with peripheral neuropathic pain. Pain Pract. 2021;21(5):536–546. doi:10.1111/papr.12989
   PubMed Web of Science ®Google Scholar
• Dupoiron D, Jubier-Hamon S, Seegers V, et al. Peripheral neuropathic pain following breast cancer: effectiveness and tolerability of high-concentration capsaicin patch. J Pain Res. 2022;15:241–255. doi:10.2147/JPR.S341378
   PubMed Web of Science ®Google Scholar
• Tenreiro Pinto J, Pereira FC, Loureiro MC, Gama R, Fernandes HL. Efficacy analysis of capsaicin 8% patch in neuropathic peripheral pain treatment. Pharmacology. 2018;101(5–6):290–297. doi:10.1159/000487444
   PubMed Web of Science ®Google Scholar
• Knolle E, Zadrazil M, Kovacs GG, Medwed S, Scharbert G, Schemper M. Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study. Pain. 2013;154(12):2729–2736. doi:10.1016/j.pain.2013.08.001
   PubMed Web of Science ®Google Scholar
• Peppin JF, Majors K, Webster LR, Simpson DM, Tobias JK, Vanhove GF. Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. J Pain Res. 2011;4:385–392. doi:10.2147/JPR.S22954
   PubMedGoogle Scholar